Anti-BAFFR Antibody Formulation Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of anti-BAFFR antibodies often have short shelf lives due to chemical and physical instabilities, leading to aggregation, deamidation, and oxidation, which can result in reduced biological activity and increased immune response.
Innovation Solution
The development of an aqueous pharmaceutical composition and a lyophilisate formulation of anti-BAFFR antibodies, which include stabilizers like sucrose, buffering agents like histidine, surfactants like polysorbate 80, and optional free amino acids, to maintain high concentrations of the antibody while minimizing aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high concentration of anti-BAFFR antibody is formulated, then dosing volume is reduced and productivity is improved, but antibody aggregation increases and shelf life decreases
Solution Approach 1:
The patent introduces specific excipients as intermediary substances to mediate between the high antibody concentration requirement and aggregation prevention. These include: (1) Surfactants (polysorbate 80, Tween 20) that act as steric barriers preventing antibody aggregation; (2) Sugars (sucrose, trehalose, raffinose) that provide cryoprotection and maintain osmotic balance; (3) Amino acids (arginine, lysine, histidine) that act as chaotropes to disrupt aggregation-prone conformations. These intermediary substances enable high concentration formulation while maintaining antibody stability.
Solution Approach 2:
The patent systematically changes formulation parameters to achieve high concentration without aggregation. Key parameter modifications include: (1) Adjusting pH to specific ranges (6.0-7.5) to optimize antibody solubility and stability; (2) Controlling ionic strength through buffer selection; (3) Optimizing excipient concentrations (surfactant: 0.01-0.5%, sugar: 50-500 mM, amino acid: 10-100 mM); (4) Selecting appropriate antibody concentrations (50-500 mg/ml). These parameter changes enable the formulation to maintain high productivity while preventing aggregation.
2Productivity
If high concentration of anti-BAFFR antibody is formulated, then material delivery efficiency is improved, but chemical and physical instabilities increase leading to reduced shelf life
Solution Approach 1:
The patent applies preliminary protective measures during formulation to prevent degradation before it occurs. This includes: (1) Pre-formulating with stabilizing excipients that continuously protect against aggregation, deamidation, and oxidation; (2) Pre-adjusting pH and ionic strength to optimal ranges that maintain antibody stability; (3) Pre-selecting compatible excipients that do not interact adversely with the antibody. These preliminary actions ensure long shelf life while maintaining high concentration for efficient material delivery.
Solution Approach 2:
The patent creates a composite formulation system combining antibody with multiple protective excipients. This composite approach provides synergistic protection: (1) Surfactants provide steric and electrostatic protection against aggregation; (2) Sugars provide cryoprotection and osmotic balance; (3) Amino acids provide chaotropic protection against degradation. This composite material system enables high concentration formulation with extended shelf life, resolving the contradiction between productivity and reliability.
3Ease of manufacture
If conventional formulation is used, then manufacturing simplicity is maintained, but aggregation occurs leading to increased immune response and safety concerns
Solution Approach 1:
The patent introduces excipients as intermediary protective substances that prevent harmful aggregation without complicating manufacturing. The formulation remains relatively simple by using well-characterized excipients with known compatibility: (1) Surfactants like polysorbate 80 that are commonly used and easily incorporated; (2) Sugars that provide stable, non-interfering protection; (3) Amino acids that act as gentle stabilizers. These intermediaries prevent aggregation and immune responses while maintaining ease of manufacture through standard formulation techniques.
Solution Approach 2:
The patent modifies formulation parameters within practical ranges to prevent aggregation and immune responses. By adjusting pH to 6.0-7.5, controlling ionic strength, and optimizing excipient concentrations, the formulation maintains simplicity while achieving the desired safety profile. These parameter changes prevent harmful factors like aggregation without requiring complex manufacturing processes.
Data Source
AI summary
Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.